Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice
- 1 October 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (10) , 2356-2360
Abstract
Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of M. tuberculosis organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy.Keywords
This publication has 20 references indexed in Scilit:
- Mycobacterial dormancyTubercle and Lung Disease, 1995
- Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophagesAntimicrobial Agents and Chemotherapy, 1995
- Dormancy ofMycobacterium tuberculosis and latency of diseaseEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Preventive Therapy of Tuberculosis with Rifapentine in Immunocompetent and Nude MiceAmerican Journal of Respiratory and Critical Care Medicine, 1994
- Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine modelAntimicrobial Agents and Chemotherapy, 1994
- Activity of levofloxacin in a murine model of tuberculosisAntimicrobial Agents and Chemotherapy, 1994
- Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosisTubercle and Lung Disease, 1992
- Activity in vitro of Rifabutin, FCE 22807, Rifapentine, and Rifampin against Mycobacterium microti and M. tuberculosis and Their Penetration into Mouse Peritoneal MacrophagesAmerican Review of Respiratory Disease, 1992
- The global tuberculosis situation and the new control strategy of the World Health OrganizationTubercle, 1991
- Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulareAntimicrobial Agents and Chemotherapy, 1985